Avillion is a clinical development and financing company that enters co-development partnerships with biopharmaceutical companies to fund and operationalize clinical trials through to regulatory approval. Avillion is backed by institutional investors which enables individual investment sizes to range from $50M to $600M. Avillion takes 100% of the clinical and regulatory risk, so if clinical and regulatory success is not achieved, the biopharma partner does not need to repay Avillion any of the monies invested. Avillion may also share in commercial risk with its co-development partners.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):